–
Статьи в журналах
-
- 2021 Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
- Vogel Arndt, Qin Shukui, Kudo Masatoshi, Su Yun, Hudgens Stacie, Yamashita Tatsuya, Yoon Jung-Hwan, Fartoux Laetitia, Simon Krzysztof, López Carlos, Sung Max, Mody Kalgi, Ohtsuka Tatsuroh, Tamai Toshiyuki, Bennett Lee, Meier Genevieve, Breder Valery
- в журнале The Lancet Gastroenterology & Hepatology, издательство Elsevier (United States), том 6, № 8, с. 649-658 DOI